Tuberculosis Diagnostics Test Market

Tuberculosis Diagnostics Test Market Size

Tuberculosis Diagnostics Test Market size was valued at USD 2.3 billion in 2023 and is anticipated to register a CAGR of over 5.5% between 2024 and 2032. Tuberculosis diagnostics tests are medical procedures and analyses employed in the detection and diagnosis of tuberculosis (TB, a bacterial infection caused by Mycobacterium tuberculosis. These tests are crucial for identifying individuals with active TB disease or latent TB infection, enabling prompt treatment and prevention efforts. The rising prevalence of TB significantly fuels the market.

For instance, according to World Health Organization (WHO), in 2022, TB caused 1.3 million deaths, including 167,000 co-infected with HIV, making it the second leading infectious cause of death worldwide, surpassing HIV/AIDS. There were around 10.6 million new TB cases, affecting 5.8 million men, 3.5 million women, and 1.3 million children, highlighting its global prevalence across all demographics. Thus, as the incidence of TB increases globally, there is a higher demand for early detection and effective treatment, prompting healthcare providers and diagnostic companies to innovate and adopt advanced technologies, stimulating market growth.

Furthermore, the adoption of Point-of-Care Testing (POCT) which is estimated to reach USD 78 billion revenue by 2032, which involves conducting diagnostic tests at or near the patient's location, is a key driver due to its rapid results and ability to facilitate immediate treatment initiation. Particularly crucial for tuberculosis, where early detection is paramount, POCT proves invaluable in regions with limited access to centralized laboratories.

Tuberculosis Diagnostics Test Market Trends

Growing awareness and screening programs for tuberculosis are stimulating the market. Increased public consciousness and proactive screening efforts, led by various organizations, encourage early detection and intervention.

• For instance, the Minnesota Department of Health has formulated screening guidelines for post-secondary school students, highlighting a focus on targeted screening for those at the greatest risk of tuberculosis.
  
• Thus, such initiative by government will pose positive impact on the market by fostering a timely response to tuberculosis, reducing its overall burden, and enhancing healthcare professionals' diagnostic capabilities.
  
• Furthermore, the development of innovative and more effective diagnostic methods serves as a significant catalyst, as it enhances the accuracy, efficiency, and accessibility of tuberculosis testing. For instance, Nucleic Acid Amplification Tests (NAATs) have elevated the precision and speed of tuberculosis (TB) diagnosis, particularly in individuals with paucibacillary disease and those living with HIV.
  
• Thus, these technological advancements contribute to early and precise detection of tuberculosis cases, fostering better patient outcomes and management.
  
• Therefore, the continuous progress in diagnostic techniques not only addresses the challenges posed by tuberculosis but also propel the market progress accessibility of tuberculosis testing.
  

Tuberculosis Diagnostics Test Market Analysis

Learn more about the key segments shaping this market

Download Free PDF

The market by test type is categorized into radiographic method, diagnostic laboratory methods, molecular diagnostics, detection of latent infection, cytokine detection assay, detection of drug resistance (DST), phage assay, and other test types. The diagnostic laboratory methods segment is further bifurcated into microscopy, culture-based techniques, and serological tests. This segment garnered USD 836 million revenue size in the year 2023.

• This growth can be attributed to the reliability and comprehensive nature of diagnostic laboratory methods in tuberculosis testing. Diagnostic laboratory methods, incorporating sophisticated techniques such as microscopy, and culture-based methods, offer highly accurate and detailed results, contributing to a more precise diagnosis of tuberculosis.
  
• Additionally, smear microscopy, a fundamental and widely used tuberculosis diagnostic method, contributing to the growth of diagnostic laboratory methods segment.
  
• Thus, this underscores the significance of diagnostic laboratories in providing effective and reliable tuberculosis testing solutions, solidifying their dominance in the market.

Learn more about the key segments shaping this market

Download Free PDF

Based on end-use, the tuberculosis diagnostics test market unfolds its segmentation, encompassing the domains of pathological laboratories, point of care testing (POCT), and other end users. The pathological laboratories segment garnered USD 1.20 billion revenue size in the year 2023.

• The segment’s supremacy is attributed due to their crucial role in conducting sophisticated diagnostic tests, including Nucleic Acid Amplification Tests (NAATs), molecular assays and other pathological screening.
  
• These laboratories ensure precision through stringent quality control measures, offering widespread accessibility and convenience.
  
• Thus, as centralized hubs for diagnostic services, they play a vital role in delivering accurate and timely tuberculosis diagnostic solutions.

Looking for region specific data?

Download Free PDF

U.S. tuberculosis diagnostics test market accounted for USD 846 million revenue size in 2023 and is predicted to witness substantial market growth over the analysis timeline.

• The dominance of the U.S. in the market is attributed to the country's advanced healthcare infrastructure, a robust research and development landscape, and a high prevalence of TB.
  
• For instance, in 2022, there was a second consecutive annual increase in the reported cases of tuberculosis (TB) in the U.S., according to the Centers for Disease Control and Prevention (CDC). The reported cases reached 8,300, with an incidence rate of 2.5 cases per 100,000 people.
  
• Thus, as the incidence of TB rises, there is a growing demand for effective diagnostic solutions, thereby stimulating market growth in the region.
  
• Furthermore, the region's proactive approach to adopting emerging technologies, coupled with the presence of key industry players and collaborations between academia and the healthcare sector, continues to propel market expansion in the region.
  

Tuberculosis Diagnostics Test Market Share

The tuberculosis diagnostics test industry is consolidated, with key players including Abbott Laboratories, Becton, Dickinson and Company (BD), F. Hoffmann-La Roche Ltd, Qiagen N.V., and others dominating the market. These companies focus on ongoing product innovation, geographical expansion, and partnerships to secure substantial market shares.

For instance, in January 2023, QIAGEN announced an exclusive strategic collaboration with Helix, a population genomics leader based in California, aimed at advancing companion diagnostics for hereditary diseases. In this partnership, QIAGEN leveraged its biopharma relationships, Next-Generation Sequencing (NGS) capabilities, and global regulatory expertise through the Helix Laboratory Platform. The collaboration marked a significant step forward, enhancing critical access to genomic testing for patients and healthcare providers combating life-threatening conditions. Additionally, it positioned QIAGEN with a competitive edge in the diagnostic market.

Tuberculosis Diagnostics Test Market Companies

Some of the eminent market participants operating in the tuberculosis diagnostics test industry include:

• Abbott Laboratories
• Becton, Dickinson and Company (BD)
• bioMerieux SA
• Cepheid (Danaher Corporation)
• F. Hoffmann-La Roche Ltd.
• Hologic, Inc.
• Hain Lifescience GmbH
• Oxford Immunotec (PerkinElmer)
• Qiagen N.V.
• Roche Molecular Systems Inc.
• Siemens Healthineers AG
• Thermo Fisher Scientific Inc.
  

Tuberculosis Diagnostics Test Industry News:

• In November 2023, BD and Bio Farma signed an MOU to collaboratively address tuberculosis. BD provided access to its advanced TB diagnostics, and the partnership optimized the TB solutions supply chain in Indonesia. This alliance expanded BD's geographical reach and boosted revenue.
  
• In February 2023, Thermo Fisher Scientific introduced real-time PCR kits for detecting infectious diseases in India, covering a spectrum of diseases, including genetic analysis (HLA B27), Multi-Drug Resistant Tuberculosis (MTB MDR), Hepatitis B Virus (HBV), M. Tuberculosis complex (MTB), Human Immunodeficiency Virus (HIV), and Hepatitis C Virus (HCV). Authorized by the Central Drugs Standard Control Organization (CDSCO), these kits were manufactured in collaboration with Mylab Discovery Solutions, enhancing the company's presence and establishing a competitive advantage in the Indian market, ultimately contributing to increased revenue.
  

Tuberculosis diagnostics test market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD from 2018 – 2032 for the following segments:

Click here to Buy Section of this Report

By Test Type, 2018 – 2032 (USD Million)

• Radiographic method
• Diagnostic laboratory methods
  • Microscopy
  • Culture-based techniques
  • Serological tests 
• Molecular diagnostics
  • Polymerase chain reaction (PCR)
  • Nucleic acid amplification tests (NAAT)
  • GeneXpert MTB/RIF
• Detection of latent infection
  • Tuberculin skin test (TST)
  • Interferon-gamma release assays (IGRAs)
• Cytokine detection assay
• Detection of drug resistance (DST)
• Phage assay
• Other test types

By End-use, 2018 – 2032 (USD Million)

• Pathological laboratories
• Point of care testing (POCT)
• Other end users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East and Africa